
    
      This is an open label study to assess, in a stepwise approach across 4 age cohorts from
      oldest to youngest (birth to <age 18), the efficacy and safety of clevidipine exposure for a
      minimum of 30 minutes and up to a maximum of 96 hours in pediatric participants undergoing a
      surgical procedure with anesthesia for greater than or equal to 1 hour and for whom
      parenteral intravenous antihypertensive therapy for the management of blood pressure is
      expected.
    
  